Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $65.0 in the prior trading day, Mirum Pharmaceuticals Inc (NASDAQ: MIRM) closed at $64.1, down -1.38%. In other words, the price has decreased by -$1.38 from its previous closing price. On the day, 0.53 million shares were traded. MIRM stock price reached its highest trading level at $65.75 during the session, while it also had its lowest trading level at $63.232.
Ratios:
Our goal is to gain a better understanding of MIRM by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.82 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 74.75. For the most recent quarter (mrq), Quick Ratio is recorded 3.16 and its Current Ratio is at 3.31. In the meantime, Its Debt-to-Equity ratio is 1.09 whereas as Long-Term Debt/Eq ratio is at 1.08.
Upgrades & Downgrades
In the most recent recommendation for this company, TD Cowen on September 24, 2025, initiated with a Buy rating and assigned the stock a target price of $95.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when GREY MICHAEL G sold 50,000 shares for $74.00 per share. The transaction valued at 3,700,000 led to the insider holds 0 shares of the business.
MICHAEL GREY bought 50,000 shares of MIRM for $3,700,000 on Dec 01 ’25. On Nov 21 ’25, another insider, GREY MICHAEL G, who serves as the Director of the company, sold 50,000 shares for $70.00 each. As a result, the insider received 3,500,000 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MIRM now has a Market Capitalization of 3312933888 and an Enterprise Value of 3237544192. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.02 while its Price-to-Book (P/B) ratio in mrq is 11.26. Its current Enterprise Value per Revenue stands at 6.862 whereas that against EBITDA is -184.318.
Stock Price History:
The Beta on a monthly basis for MIRM is 0.51, which has changed by 0.52403283 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, MIRM has reached a high of $78.54, while it has fallen to a 52-week low of $36.88. The 50-Day Moving Average of the stock is -9.28%, while the 200-Day Moving Average is calculated to be 11.17%.
Shares Statistics:
The stock has traded on average 660.17K shares per day over the past 3-months and 720070 shares per day over the last 10 days, according to various share statistics. A total of 51.31M shares are outstanding, with a floating share count of 42.49M. Insiders hold about 17.79% of the company’s shares, while institutions hold 96.39% stake in the company. Shares short for MIRM as of 1764288000 were 7464991 with a Short Ratio of 11.31, compared to 1761868800 on 7027185. Therefore, it implies a Short% of Shares Outstanding of 7464991 and a Short% of Float of 14.530000000000001.
Earnings Estimates
. The current rating of Mirum Pharmaceuticals Inc (MIRM) reflects the combined expertise of 6.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.07, with high estimates of $0.08 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.18 and -$0.61 for the fiscal current year, implying an average EPS of -$0.38. EPS for the following year is -$0.01, with 7.0 analysts recommending between $0.97 and -$0.73.
Revenue Estimates
8 analysts predict $135.76M in revenue for. The current quarter. It ranges from a high estimate of $138.6M to a low estimate of $131.3M. As of. The current estimate, Mirum Pharmaceuticals Inc’s year-ago sales were $99.41MFor the next quarter, 8 analysts are estimating revenue of $142.31M. There is a high estimate of $149M for the next quarter, whereas the lowest estimate is $137.89M.
A total of 9 analysts have provided revenue estimates for MIRM’s current fiscal year. The highest revenue estimate was $511M, while the lowest revenue estimate was $503.7M, resulting in an average revenue estimate of $507.88M. In the same quarter a year ago, actual revenue was $336.89MBased on 9 analysts’ estimates, the company’s revenue will be $609.05M in the next fiscal year. The high estimate is $659.6M and the low estimate is $574.1M.
